UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 24, 2017
Intersect ENT, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 001-36545 | | 20-0280837 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer
Identification No.) |
Intersect ENT, Inc.
1555 Adams Drive
Menlo Park, California 94025
(Address of principal executive offices, including zip code)
(650)641-2100
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule14a-12 under the Exchange Act (17 CFR240.14a-12) |
| ☐ | Pre-commencement communications pursuant toRule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant toRule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) |
| Item 7.01 | Regulation FD Disclosure |
On February 24, 2017, Intersect ENT, Inc. (the “Company”) issued a press release announcing that the Company has received approval from the U.S. Food and Drug Administration (“FDA”) for its PROPEL® Contour steroid releasing sinus implant. A copy of the Company press release is furnished and attached as Exhibit 99.1.
The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form8-K are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 as amended (Exchange Act), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (Securities Act). The information in this Item 7.01 and Exhibit 99.1 shall not be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 9.01 | Financial Statements and Exhibits. |
| | |
Exhibit No. | | Description |
| |
| 99.1 | | Press release entitled “Intersect ENT Announces FDA Approval of Newest Steroid Releasing Implant, PROPEL® Contour, for Use in Treating the Frontal and Maxillary Sinuses” dated February 24, 2017. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| | | | Intersect ENT, Inc. |
| | |
| Dated: February 24, 2017 | | | | |
| | | |
| | | | By: | | /s/ David A. Lehman |
| | | | | | David A. Lehman |
| | | | | | General Counsel |
INDEX TO EXHIBITS
| | |
Exhibit No. | | Description |
| |
| 99.1 | | Press release entitled “Intersect ENT Announces FDA Approval of Newest Steroid Releasing Implant, PROPEL® Contour, for Use in Treating the Frontal and Maxillary Sinuses” dated February 24, 2017. |
